Replying to:
Thursday 15 September 2016
Y. Shaked and al. from the Israel Institute of Technology, The University of Texas M. D. Anderson Cancer Center and the Sunnybrook Research Institute have just published in Cancer Research an article entitled: Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy where they show the impact of metronomic capecitabine on the immune system and their potential anti-tumoral effects.
Abstract
Background : Conventional chemotherapy drugs administered (...)